» Articles » PMID: 26552420

Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study

Abstract

Purpose: Type II ovarian cancer (OC) and endometrial cancer (EC) are generally diagnosed at an advanced stage, translating into a poor survival rate. There is increasing evidence that Müllerian duct cancers may exfoliate cells. We have established an approach for lavage of the uterine cavity to detect shed cancer cells.

Patients And Methods: Lavage of the uterine cavity was used to obtain samples from 65 patients, including 30 with OC, five with EC, three with other malignancies, and 27 with benign lesions involving gynecologic organs. These samples, as well as corresponding tumor tissue, were examined for the presence of somatic mutations using massively parallel sequencing (next-generation sequencing) and, in a subset, singleplex analysis.

Results: The lavage technique could be applied successfully, and sufficient amounts of DNA were obtained in all patients. Mutations, mainly in TP53, were identified in 18 (60%) of 30 lavage samples of patients with OC using next-generation sequencing. Singleplex analysis of mutations previously determined in corresponding tumor tissue led to further identification of six patients. Taken together, in 24 (80%) of 30 patients with OC, specific mutations could be identified. This also included one patient with occult OC. All five analyzed lavage specimens from patients with EC harbored mutations. Eight (29.6%) of 27 patients with benign lesions tested positive for mutations, six (75%) as a result of mutations in the KRAS gene.

Conclusion: This study proved that tumor cells from ovarian neoplasms are shed and can be collected via lavage of the uterine cavity. Detection of OC and EC and even clinically occult OC was achieved, making it a potential tool of significant promise for early diagnosis.

Citing Articles

Identification of cancer driver mutations in liquid-based cytology samples for the screening of endometrial diseases.

Matsuura M, Takane K, Yamaguchi K, Ikenoue T, Hatakeyama S, Kurokawa S BJC Rep. 2024; 1(1):18.

PMID: 39516270 PMC: 11524081. DOI: 10.1038/s44276-023-00020-y.


The Role of Circulating Tumor DNA in Ovarian Cancer.

Golara A, Kozlowski M, Cymbaluk-Ploska A Cancers (Basel). 2024; 16(18).

PMID: 39335089 PMC: 11430586. DOI: 10.3390/cancers16183117.


Single-molecule epiallelic profiling of DNA derived from routinely collected Pap specimens for noninvasive detection of ovarian cancer.

OKeefe C, Zhao Y, Cope L, Ho C, Fader A, Stone R Clin Transl Med. 2024; 14(8):e1778.

PMID: 39083293 PMC: 11290349. DOI: 10.1002/ctm2.1778.


Cervicovaginal specimen biomarkers for early detection of ovarian and endometrial cancer: A review.

Kwinten K, Lemain V, de Hullu J, Leenders W, Steenbeek M, Van Altena A Cancer Med. 2024; 13(14):e70000.

PMID: 39031958 PMC: 11259558. DOI: 10.1002/cam4.70000.


Clinical relevance of circulating tumor DNA in ovarian cancer: current issues and future opportunities.

Trevisi E, Sessa C, Colombo I Explor Target Antitumor Ther. 2024; 5(3):627-640.

PMID: 38966171 PMC: 11220313. DOI: 10.37349/etat.2024.00239.


References
1.
. National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol. 1994; 55(3 Pt 2):S4-14. DOI: 10.1006/gyno.1994.1333. View

2.
Kinde I, Bettegowda C, Wang Y, Wu J, Agrawal N, Shih I . Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med. 2013; 5(167):167ra4. PMC: 3757513. DOI: 10.1126/scitranslmed.3004952. View

3.
Kessler M, Fotopoulou C, Meyer T . The molecular fingerprint of high grade serous ovarian cancer reflects its fallopian tube origin. Int J Mol Sci. 2013; 14(4):6571-96. PMC: 3645655. DOI: 10.3390/ijms14046571. View

4.
Bijron J, Seldenrijk C, Zweemer R, Lange J, Verheijen R, van Diest P . Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis. Am J Surg Pathol. 2013; 37(8):1123-30. DOI: 10.1097/PAS.0b013e318282da7f. View

5.
Bettegowda C, Sausen M, Leary R, Kinde I, Wang Y, Agrawal N . Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6(224):224ra24. PMC: 4017867. DOI: 10.1126/scitranslmed.3007094. View